Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards its goal of creating new standards of care for patients with cancer will include six late-breaking presentations, including two ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

2,3 Patient comorbidities and frailty may unnecessarily affect CVD management. 4,5,6 Daiichi Sankyo remains committed to its promise to continue expanding medical knowledge to support better CV ...

Bài chạy dài đem lại nhiều lợi ích về thể lực, sức bền và ý chí, nhưng cũng đòi hỏi runner phải có kế hoạch và sự chuẩn bị chi tiết. Dù bạn đang chuẩn bị cho cuộc đua 5km, 10km, bán marathon (21 ...

The "Vietnamese Ao Dai Tourism Festival 2024" is set to be a grand celebration of Vietnam’s traditional attire, bringing together the country's most esteemed designers to showcase their unique Ao Dai ...

"We are at the start line of our new chapter," said Shun, looking at Dai. "I am so happy to be here with you." The video gained over 500,000 views in just ten hours, and now has 1.4 million views.

A crypto whale lost over $55 million in DAI after unknowingly signing an unverified transaction. Chainalysis reports that more than $2.7 billion has been lost to such attacks since May 2021.

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Daiichi Sankyo’s antibody-drug conjugate (ADC) platform has already delivered one drug to the market with blockbuster sales forecasts, with a second due to be filed shortly. Now, a third is ...